William Guyer - 13 Feb 2022 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
15 Feb 2023, 19:02:37 UTC
Prior SEC filing
11 Feb 2022
Next SEC filing
06 Sep 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer

Key filing fact

William Guyer filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 15 Feb 2023.

Key facts

  • This page summarizes William Guyer's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 15 Feb 2023, 19:02.

Change

  • Previous filing in this sequence was filed on 11 Feb 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CORT transaction Derivative

Stock option (right to buy)

Award

Transaction value
$0
Shares
+200,000
Change %
Price
$0.000000
Shares after
200,000
Date
13 Feb 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
200,000
Exercise price
$23.06
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period.

SEC remarks

The power of attorney under which this form was signed is on file with the Commission.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .